A biomarker is a measurable indicator of a normal biological process, a pathogenic process, or a response to an intervention, and it may be molecular, imaging, physiologic, or digital. In translation and localization, it appears in clinical trial protocols, informed consent forms, diagnostic product information, regulatory submissions, and study reports that describe endpoints or patient selection.
Biomarker appears in clinical study titles, eligibility criteria, statistical analysis plans, diagnostic labeling, and regulatory submissions. Translators may work with compound markers, biomarker-positive patients, and companion diagnostics, often needing to preserve established abbreviations, cut-off values, and units in lab reports, informed consent forms, and patient-facing summaries without introducing unexplained variants.
A common mistake is translating biomarker as 'biological marker' in all patient materials without recognizing that 'biomarker' is often the preferred scientific term. Overliteral expansion can also create inconsistencies with companion diagnostics, trial endpoints, and regulatory text where the term is used as a fixed concept.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →